Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity associated with clinically significant impairment in functioning. ADHD has an early onset, but frequently persists, with a prevalence estimate of 4% in adults. Dasotraline is a novel compound that is a potent inhibitor of dopamine and norepinephrine transporters that achieves stable plasma concentrations with once-daily dosing. In this study, adult outpatients meeting DSM-IV-TR criteria for ADHD were randomized to 4 weeks of double-blind, once-daily treatment with dasotraline 4 and 8 mg/day or placebo. The primary efficacy end point was change from baseline at week 4 in the ADHD Rating Scale, Version IV (ADHD RS-IV) total score. Secondary efficacy end points included the Clinical Global Impression, Severity (CGI-S) scale, modified for ADHD symptoms. Least squares (LS) mean improvements at week 4 in ADHD RS-IV total score were significantly greater for dasotraline 8 mg/day vs placebo (-13.9 vs -9.7; P=0.019), and nonsignificantly greater for 4 mg/day (-12.4; P=0.076). The LS mean improvements in modified CGI-S were significantly greater at week 4 for dasotraline 8 mg/day vs placebo (-1.1 vs -0.7; P=0.013), and for 4 mg/day vs placebo (-1.1 vs -0.7; P=0.021). The most frequent adverse events reported were insomnia, decreased appetite, nausea, and dry mouth. Discontinuations due to treatment-emergent adverse events were 10.3% and 27.8% of patients in 4 and 8 mg/day treatment groups, respectively. This study provides preliminary evidence that once-daily dosing with dasotraline, a long-acting, dual monoamine reuptake inhibitor, may be a safe and efficacious treatment for adult ADHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of the Insomnia Severity Index as an outcome measure for insomnia research
Bastien, C. (2001) · Sleep Medicine · doi:10.1016/s1389-9457(00)00065-4 · Cited by 8,067 · cited 1×
“The severity of insomnia and insomnia-related interference with daytime functioning was assessed using the 7-item Insomnia Severity Index (ISI; Bastien et al, 2001); risk of drug withdrawal was evaluated using the 20-item Physician Withdrawal Checklist (PWC; Rickels et al, 2008); an Abuse Potential…”
MethodPosner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886 · cited 1×
“ADHD affects 5–7% of children (based on DSM-IVTR criteria; Polanczyk et al, 2014), and frequently persists into adulthood, with prevalence estimates of 4% in adults (Faraone and Biederman, 2005; Kessler et al, 2006).”
BackgroundMolecular genetics of attention-deficit/hyperactivity disorder
Faraone, S. V., Perlis, R. H., Doyle, A. E., Smoller, J. W., Goralnick, J. J., Holmgren, M. A., & Sklar, P. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.024 · Cited by 2,357 · cited 1×
“Dopamine (DA) and norepinephrine (NE) have been implicated in the pathophysiology of ADHD, and drugs that increase DA and NE neurotransmission are clinically useful in ADHD symptom management (Faraone et al, 2005).”
BackgroundPolanczyk, G. V., Willcutt, E. G., Salum, G. A., Kieling, C., & Rohde, L. A. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyt261 · Cited by 1,822 · cited 1×
“ADHD affects 5–7% of children (based on DSM-IVTR criteria; Polanczyk et al, 2014), and frequently persists into adulthood, with prevalence estimates of 4% in adults (Faraone and Biederman, 2005; Kessler et al, 2006).”
BackgroundVolkow, N. D. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180042006 · Cited by 575 · cited 1×
“Delayed absorption and/or maintenance of steady plasma concentrations is known to reduce the abuse potential of stimulant drugs (Volkow et al, 1995; Kollins et al, 1998; Spencer et al, 2012).”
BackgroundFaraone, S. V., Spencer, T., Aleardi, M., Pagano, C., & Biederman, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000108984.11879.95 · Cited by 404
Faraone, S. V., & Glatt, S. J. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04902pur · Cited by 387
The drug effects questionnaire: psychometric support across three drug types
Morean, M. E., de Wit, H., King, A. C., Sofuoglu, M., Rueger, S. Y., & O’Malley, S. S. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2954-z · Cited by 252
Hannestad, J., Gallezot, J.-D., Planeta-Wilson, B., Lin, S.-F., Williams, W. A., van Dyck, C. H., Malison, R. T., Carson, R. E., & Ding, Y.-S. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.017 · Cited by 236
Koesters, M., Becker, T., Kilian, R., Fegert, J., & Weinmann, S. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108092338 · Cited by 142 · cited 1×
“…at week 4 overlapped with the range and 95% confidence intervals of those reported in meta-analyses of the DAT/NET inhibitor methylphenidate (Faraone et al, 2004; Koesters et al, 2009), but were smaller than the effect sizes reported for amphetamine-based medications (Faraone and Glatt, 2010).”
ResultPeterson, K., McDonagh, M. S., & Fu, R. (2008) · Psychopharmacology · doi:10.1007/s00213-007-0996-4 · Cited by 135 · cited 1×
“The rates of insomnia at the 4 mg/day dose were comparable to rates observed for stimulant drugs such as methylphenidate (Peterson et al, 2008), whereas higher rates were observed for the 8 mg/day dose.”
The reliability and validity of self-and investigator ratings of ADHD in adults
Adler, L. A., Faraone, S. V., Spencer, T. J., Michelson, D., Reimherr, F. W., Glatt, S. J., Marchant, B. K., & Biederman, J. (2008) · Journal of Attention Disorders · doi:10.1177/1087054707308503 · Cited by 108 · cited 1×
“The primary efficacy measure was the ADHD Rating Scale, Version IV (ADHD RS-IV, with adult prompts; Adler et al, 2008), an 18-item scale based on DSM-IV-TR criteria that consists of a total score, and Hyperactivity/Impulsivity and Inattentiveness subscale scores.”
MethodVincent, S., Bieck, P. R., Garland, E. M., Loghin, C., Bymaster, F. P., Black, B. K., Gonzales, C., Potter, W. Z., & Robertson, D. (2004) · Circulation · doi:10.1161/01.cir.0000130847.18666.39 · Cited by 102 · cited 1×
“Dasotraline at 4 and 8mg/day also decreased circulating DHPG levels, indicative of central inhibition of norepinephrine transporters (Vincent et al, 2004).”
BackgroundPsychometric properties of the Wender-Reimherr Adult Attention Deficit Disorder Scale.
Marchant, B. K., Reimherr, F. W., Robison, D., Robison, R. J., & Wender, P. H. (2013) · Psychological Assessment · doi:10.1037/a0032797 · Cited by 63
Physician Withdrawal Checklist (PWC-20)
Rickels, K., Garcia-Espana, F., Mandos, L. A., & Case, G. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31817efbac · Cited by 59 · cited 1×
“…Insomnia Severity Index (ISI; Bastien et al, 2001); risk of drug withdrawal was evaluated using the 20-item Physician Withdrawal Checklist (PWC; Rickels et al, 2008); an Abuse Potential Monitoring Plan was implemented that included monitoring of sentinel adverse events and medication handling…”
Method
Cited by
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Treatment strategies for ADHD: an evidence-based guide to select optimal treatment
Caye, A., Swanson, J. M., Coghill, D., & Rohde, L. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0116-3 · Cited by 303
Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses
Chierrito de Oliveira, D., Guerrero de Sousa, P., Borges dos Reis, C., Tonin, F. S., Maria Steimbach, L., Virtuoso, S., Fernandez-Llimos, F., Pontarolo, R., & Cristina Conegero Sanches, A. (2019) · Journal of Attention Disorders · doi:10.1177/1087054717696773 · Cited by 14
Maletic, V., Mattingly, G. W., & Earnest, J. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2327533 · Cited by 2
Metadata
- Authors
- Koblan, K. S., Hopkins, S. C., Sarma, K., Jin, F., Goldman, R., Kollins, S. H., & Loebel, A.
- Venue
- Neuropsychopharmacology
- Published
- 2015-05-07
- Volume
- 40
- Issue
- 12
- Pages
- 2745-2752
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1767927283
- Cited by
- 62
- References
- 16
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.